keyword
MENU ▼
Read by QxMD icon Read
search

Macular edema anti-VEGF

keyword
https://www.readbyqxmd.com/read/28642823/visualization-of-changes-in-the-foveal-avascular-zone-in-both-observed-and-treated-diabetic-macular-edema-using-optical-coherence-tomography-angiography
#1
Aditya Gill, Emily D Cole, Eduardo A Novais, Ricardo N Louzada, Talisa de Carlo, Jay S Duker, Nadia K Waheed, Caroline R Baumal, Andre J Witkin
BACKGROUND: Central vision loss in diabetic retinopathy is commonly related to diabetic macular edema (DME). The objective of this study was to describe changes between consecutive visits on optical coherence tomography angiography (OCTA) of the foveal avascular zone (FAZ) in eyes with DME. METHODS: 20 eyes from 14 patients with DME were imaged on 2 successive clinic visits separated by at least 1 month. The mean interval between visits was 3.2 months. The only intervention used was intravitreal anti-VEGF in 11 eyes; the others were observed over time without treatment...
2017: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/28638337/intravitreal-anti-vascular-endothelial-growth-factor-for-macular-edema-due-to-complex-retinal-arterial-macroaneurysms
#2
Caroline Bormann, Jens Heichel, Ute Hammer, Anke Habermann, Thomas Hammer
INTRODUCTION: Complex retinal arterial macroaneurysms (RAM) are often accompanied by hemorrhage and/or affect the macula. We evaluated the effect of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy using ranibizumab or aflibercept with or without laser photocoagulation in the treatment of macular edema due to RAM. METHODS: A case report of two patients with secondary macular edema caused by RAM is presented. The first case was a 76-year-old female treated with two 0...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28625129/triamcinolone-acetonide-suppresses-inflammation-and-facilitates-vascular-barrier-function-in-human-retinal-microvascular-endothelial-cells
#3
Shunsuke Imai, Tomohiro Otsuka, Akira Naito, Masamitsu Shimazawa, Hideaki Hara
BACKGROUND: Diabetic macular edema (DME) is resulted from the retinal microvascular leakage that accompanies the breakdown of blood-retinal barrier. Triamcinolone acetonide (TA) is a therapeutic agent for DME, but since the detailed mechanism of action of TA is not known, part of its action was examined. METHODS: In vitro model to enhance the permeability of human retinal microvascular endothelial cells (HRMECs) was constructed by using DME-related cytokines such as vascular endothelial growth factor (VEGF), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β)...
June 18, 2017: Current Neurovascular Research
https://www.readbyqxmd.com/read/28601428/vegf-production-and-signaling-in-m%C3%A3-ller-glia-are-critical-to-modulating-vascular-function-and-neuronal-integrity-in-diabetic-retinopathy-and-hypoxic-retinal-vascular-diseases
#4
Yun-Zheng Le
Müller glia (MG) are major retinal supporting cells that participate in retinal metabolism, function, maintenance, and protection. During the pathogenesis of diabetic retinopathy (DR), a neurovascular disease and a leading cause of blindness, MG modulate vascular function and neuronal integrity by regulating the production of angiogenic and trophic factors. In this article, I will (1) briefly summarize our work on delineating the role and mechanism of MG-modulated vascular function through the production of vascular endothelial growth factor (VEGF) and on investigating VEGF signaling-mediated MG viability and neural protection in diabetic animal models, (2) explore the relationship among VEGF and neurotrophins in protecting Müller cells in in vitro models of diabetes and hypoxia and its potential implication to neuroprotection in DR and hypoxic retinal diseases, 7and (3) discuss the relevance of our work to the effectiveness and safety of long-term anti-VEGF therapies, a widely used strategy to combat DR, diabetic macular edema, neovascular age-related macular degeneration, retinopathy of prematurity, and other hypoxic retinal vascular disorders...
June 7, 2017: Vision Research
https://www.readbyqxmd.com/read/28598120/-characteristics-and-clinical-significance-of-outer-retinal-tubulation-in-wet-age-macular-degeneration-treated-by-anti-vascular-endothelial-growth-factor-through-optical-coherence-tomography
#5
Cheng Zuo, Xun Li, Zi-Rong Zhang, Mei-Xia Zhang
OBJECTIVES: To determine the characteristics and clinical significance of outer retinal tabulation (ORT) in wet age-related macular degeneration (wAMD) treated by anti-vascular endothelial growth factor (anti-VEGF) through optical coherence tomography (OCT). METHODS: The 35 wAMD patients with 39 ORT eyes treated by anti-VEGF were examined by OCT to determine the morphological features and evolution of the ORTs over time and their response to anti-VEGF. RESULTS: ORTs were located in the places that exudation or edema had happened in the outer nuclear layer of retina...
November 2016: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
https://www.readbyqxmd.com/read/28564655/aqueous-humor-levels-of-soluble-vascular-endothelial-growth-factor-receptor-and-inflammatory-factors-in-diabetic-macular-edema
#6
Hidetaka Noma, Tatsuya Mimura, Kanako Yasuda, Ryosuke Motohashi, Osamu Kotake, Masahiko Shimura
Aqueous levels of soluble vascular endothelial growth factor receptor (sVEGFR) and inflammatory factors were measured in 35 patients (37 eyes) with diabetic macular edema (DME) receiving anti-vascular endothelial growth factor (VEGF) therapy. Aqueous levels of growth factors (VEGF, placental growth factor [PlGF], and platelet-derived growth factor AA [PDGF-AA]), sVEGFR-1 and -2, soluble intercellular adhesion molecule 1, monocyte chemotactic protein (MCP)-1, interleukin (IL)-6, -8, -12, and -13, and interferon-inducible 10-kDa protein (IP-10) were significantly higher in the DME group than in the nondiabetic control group...
June 1, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28559839/branch-retinal-vein-occlusion-macular-ischemia-and-intravitreal-anti-vegf-therapy
#7
Thomas Bertelmann, Hans Ulrich Frank, Hendrik Ansgar Fuchs, Nicolas Feltgen
PURPOSE: To report a case with ischemic macular edema (ME) due to an acute branch retinal vein occlusion (BRVO) which was treated with repeated intravitreal anti-VEGF injections. METHODS: Retrospective case presentation. RESULTS: A 66-year-old female patient was treated with repeated intravitreal anti-VEGF injections due to ischemic ME following an acute BRVO. Over a period of 2.5 years best corrected visual acuity increased from 0.06 to 0...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28559722/topical-versus-subconjunctival-anti-vascular-endothelial-growth-factor-therapy-bevacizumab-ranibizumab-and-aflibercept-for-treatment-of-corneal-neovascularization
#8
REVIEW
Tariq Al-Debasi, Abdulkareem Al-Bekairy, Abdulmalik Al-Katheri, Shmeylan Al Harbi, Mahmoud Mansour
In order to evaluate the effect of topical and subconjunctival anti-vascular endothelial growth factor (anti-VEGF) therapy, Ranibizumab, Bevacizumab and Aflibercept as a therapy for corneal neovascularization (NV) treatment, the aim of this study was to review all data related to some of anti-VEGF as a promising therapies for corneal NV treatment. Corneal NV is a dangerous condition leading to a marked reduction in vision due to angiogenesis of abnormal vessels that block light. During the recent years, we have recognized new drug proliferation for corneal NV treatment...
April 2017: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://www.readbyqxmd.com/read/28551902/-treatment-options-for-diabetic-macular-edema
#9
REVIEW
Efraim Berco, Daniel Rappoport, Ayala Pollack
Diabetic retinopathy (DR) is the leading cause of vision loss in people under 65 years of age. Diabetic macular edema (DME) is the most common cause of moderate visual impairment in individuals with DR. Until recently, focal or grid laser photocoagulation has been the standard of care for DME. Laser photocoagulation has been shown to stabilize vision and prevent moderate vision loss. Recent studies on the effect of anti-vascular endothelial growth factor (VEGF) substances in DME, showed resolution of the edema and visual acuity gain...
February 2017: Harefuah
https://www.readbyqxmd.com/read/28551163/therapies-for-macular-edema-associated-with-branch-retinal-vein-occlusion-a-report-by-the-american-academy-of-ophthalmology
#10
Justis P Ehlers, Stephen J Kim, Steven Yeh, Jennifer E Thorne, Prithvi Mruthyunjaya, Scott D Schoenberger, Sophie J Bakri
PURPOSE: To evaluate the available evidence on the ocular safety and efficacy of current therapeutic alternatives for the management of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). METHODS: Literature searches were last conducted on January 31, 2017, in PubMed with no date restrictions and limited to articles published in English, and in the Cochrane Database without language limitations. The searches yielded 321 citations, of which 109 were reviewed in full text and 27 were deemed appropriate for inclusion in this assessment...
May 24, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28546934/foveal-thickness-reduction-after-anti-vascular-endothelial-growth-factor-treatment-in-chronic-diabetic-macular-edema
#11
Gabriel Willmann, Antonio Brunno Nepomuceno, Katharina Messias, Leticia Barroso, Ingrid U Scott, André Messias, Rodrigo Jorge
AIM: To report foveal thickness reduction in eyes with resolution of macular edema and recovery of a foveal depression after one-year of anti-vascular endothelial growth factor (anti-VEGF) therapy for center-involving diabetic macular edema (DME). METHODS: Foveal thickness was assessed with optical coherence tomography to determine the central subfield foveal thickness (CSFT) and macular volume in 42 eyes with DME (CSFT>275 µm). Evaluations also included measurement of best-corrected visual acuity (BCVA), and were performed at baseline, and upon foveal depression recovery achieved after 12 monthly intravitreal injections of either 1...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28503435/evaluation-of-hyperreflective-foci-as-a-prognostic-factor-of-visual-outcome-in-retinal-vein-occlusion
#12
Bin Mo, Hai-Ying Zhou, Xuan Jiao, Feng Zhang
AIM: To evaluate the potential role of hyperreflective foci (HF) as a prognostic indicator of visual outcome in patients with macular edema (ME) due to retinal vein occlusion (RVO). METHODS: We retrospectively reviewed 50 eyes of 50 patients with ME due to ischemic central retinal vein occlusion (CRVO), non-ischemic CRVO and branch retinal vein occlusion (BRVO) who were treated with anti-vascular endothelial growth factor (anti-VEGF) at Beijing Tongren Eye Center from January 2013 to July 2016...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28499163/the-diabetic-retinopathy-barometer-study-global-perspectives-on-access-to-and-experiences-of-diabetic-retinopathy-screening-and-treatment
#13
D Cavan, L Makaroff, J da Rocha Fernandes, M Sylvanowicz, P Ackland, J Conlon, D Chaney, A Malhi, J Barratt
AIM: To assess the level of awareness, prevention and treatment of Diabetic Eye Disease (DED) comprising Diabetic Retinopathy (DR) and Diabetic Macula Edema (DME) retinopathy among adults with diabetes and health professionals. METHODS: The Diabetic Retinopathy Barometer Study consisted of a qualitative study, which consisted of semi-structured interviews, and a quantitative study using online surveys for adults with diabetes and for health professionals. RESULTS: A total of 4340 adults with diabetes and 2329 health professionals participated in the surveys...
July 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28499051/safety-and-efficacy-of-ziv-aflibercept-in-the-treatment-of-refractory-diabetic-macular-edema
#14
Mohammed Ashraf, Hassan El Kayal, Ahmed A R Souka
BACKGROUND AND OBJECTIVE: To evaluate the safety and efficacy of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Bridgewater, NJ/Regeneron Pharmaceuticals, Tarrytown, NY) in the treatment of refractory diabetic macular edema (DME). PATIENTS AND METHODS: Retrospective case series looking at the safety of ziv-aflibercept in patients with DME refractory to previous anti-vascular endothelial growth factor (VEGF) therapy. Detailed ophthalmologic examination, best-corrected visual acuity, and optical coherence tomography measurements were performed pre-switch, as well as at each monthly follow-up visit...
May 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28492860/baseline-factors-associated-with-6-month-visual-acuity-and-retinal-thickness-outcomes-in-patients-with-macular-edema-secondary-to-central-retinal-vein-occlusion-or-hemiretinal-vein-occlusion-score2-study-report-4
#15
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Jacqueline King, Andrew N Antoszyk, Mark A Peters, Michael Tolentino
Importance: Macular edema (ME) is the leading cause of decreased visual acuity (VA) associated with retinal vein occlusion (RVO). Identifying factors associated with better outcomes in RVO eyes treated with anti-vascular endothelial growth factor (VEGF) therapy may provide information useful in counseling patients. Objective: To investigate baseline characteristics associated with 6-month VA and central subfield thickness (CST) outcomes in participants in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)...
June 1, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28492427/quantitative-optical-coherence-tomography-analysis-of-retinal-degenerative-changes-in-diabetic-macular-edema-and-neovascular-age-related-macular-degeneration
#16
Ernest V Boiko, Dmitrii S Maltsev
PURPOSE: To investigate the relationship of the pre-anti-vascular endothelial growth factor (VEGF) retinal tissue area (RTA) and optical density (ODRT) of the retinal optical slice portion located in the central subfield, and their ratio (RTA/ODRT), in the presence of diabetic macular edema or of inraretinal cystic fluid in neovascular age-related macular degeneration, to central retinal thickness and best-corrected visual acuity after anti-VEGF treatment with ME resolution. METHODS: The optical coherence tomography images and medical records of 33 patients (41 eyes) with neovascular age-related macular degeneration, 15 (21 eyes) with diabetic macular edema and 9 healthy individuals (15 eyes) were retrospectively analyzed...
May 10, 2017: Retina
https://www.readbyqxmd.com/read/28484955/ranibizumab-in-the-treatment-of-diabetic-macular-edema-a-review-of-the-current-status-unmet-needs-and-emerging-challenges
#17
REVIEW
Nikolaos Dervenis, Athanasia Maria Mikropoulou, Paris Tranos, Panagiotis Dervenis
Diabetic retinopathy (more specifically diabetic macular edema, DME) is the most common cause of loss of vision in the working population in developed countries. Anti-vascular endothelial growth factor (anti-VEGF) agents considerably changed the treatment algorithms and improved prognosis of center-involving DME. Ranibizumab was the first approved anti-VEGF agent that revolutionized DME treatment. The vast increase in the number of patients undergoing intravitreal treatment and the role of anti-VEGF pharmacotherapy as the mainstay of DME treatment have triggered several challenges...
May 8, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28464780/designed-ankyrin-repeat-proteins-a-look-at-their-evolving-use-in-medicine-with-a-focus-on-the-treatment-of-chorioretinal-vascular-disorders
#18
Elizabeth Smithwick, Michael W Stewart
BACKGROUND: Antibodies constitute an important drug development platform for drugs to treat several ophthalmic, oncologic, and immunologic conditions, but due to limitations inherent in antibody production and structure, a wide range of other protein binding scaffolds are being investigated. Designed ankyrin repeat proteins (DARPins) are simple to produce and offer a range of advantages over antibodies because of their stability, high binding affinity, and rigid structure. OBJECTIVE: DARPins are being developed for a wide variety of medical applications, and the most studied molecule, abicipar pegol, is used to treat chorioretinal vascular diseases...
May 1, 2017: Anti-inflammatory & Anti-allergy Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/28458584/anti-vegf-therapy-for-central-retinal-vein-occlusion-caused-by-tuberculosis-associated-uveitis-a-case-report
#19
Manzo Taguchi, Yutaka Sakurai, Takayuki Kanda, Masaru Takeuchi
BACKGROUND: Tuberculosis (TB)-associated uveitis presents periphlebitis, occasionally causing central retinal vascular occlusion (CRVO). Intravitreal injection of ranibizumab (IVR) is an effective treatment for CRVO, which improves macular edema (ME) by reducing vascular permeability and prevents progression of retinal nonperfusion in CRVO. We report a case of CRVO due to TB-associated uveitis, which initially remitted by repeated IVR as an adjunct to anti-TB therapy and systemic corticosteroids, but subsequently led to severe vitreous hemorrhage (VH)...
2017: International Medical Case Reports Journal
https://www.readbyqxmd.com/read/28448655/change-in-diabetic-retinopathy-through-2-years-secondary-analysis-of-a-randomized-clinical-trial-comparing-aflibercept-bevacizumab-and-ranibizumab
#20
Susan B Bressler, Danni Liu, Adam R Glassman, Barbara A Blodi, Alessandro A Castellarin, Lee M Jampol, Paul L Kaufman, Michele Melia, Harinderjit Singh, John A Wells
Importance: Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening. It is unknown whether these effects differ across anti-VEGF agents. Objective: To compare changes in DR severity during aflibercept, bevacizumab, or ranibizumab treatment for DME. Design, Setting, and Participants: Preplanned secondary analysis of data from a comparative effectiveness trial for center-involved DME was conducted in 650 participants receiving aflibercept, bevacizumab, or ranibizumab...
June 1, 2017: JAMA Ophthalmology
keyword
keyword
36615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"